Valuation: NetraMark Holdings Inc.

Market Cap 64.35M 45.42M 39.95M 37.78M 34.26M 4.36B 64.72M 452M 175M 2.22B 171M 167M 7.15B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 64.35M 45.42M 39.95M 37.78M 34.26M 4.36B 64.72M 452M 175M 2.22B 171M 167M 7.15B EV / Sales 2026 *
160x
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
09-10 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
09-01 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
08-14 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 day-1.45%
Current month+6.25%
3 months+9.68%
6 months-22.73%
Current year-38.18%
1 week 0.65
Extreme 0.65
0.78
1 month 0.63
Extreme 0.63
0.78
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.44
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
President - 03/07/2022
Director of Finance/CFO 57 17/07/2022
Director TitleAgeSince
Chairman 40 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Tax

General Counsel

6,944 0.0075%
01/09/26 Other

Director

0 0%
01/09/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-1.45%0.00%-55.26%+78.95% 45.42M
-1.35%+1.52%-0.44%+62.36% 3,781B
-1.15%+2.40%+5.58%+1,088.84% 451B
+0.21%+9.65%+93.21%+202.05% 96.48B
+0.17%+10.78%-6.69%+39.61% 89.97B
-1.91%+3.92%-14.38%-9.36% 80.03B
-0.64%-3.64%-46.41%+129.38% 60.58B
-4.90%-8.75%+7.13%-9.34% 45.2B
+4.05%+7.86%+180.42%+395.39% 44.07B
+0.45%-3.61%-20.99%+44.33% 37.84B
Average -0.02%+3.30%+14.22%+202.22% 468.6B
Weighted average by Cap. -0.13%+2.06%+2.72%+165.42%

Financials

2026 *2027 *
Net sales 401K 283K 249K 235K 213K 27.17M 403K 2.82M 1.09M 13.86M 1.06M 1.04M 44.55M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
28/09/26 CA$0.6800 -1.45% 29,198
25/09/26 CA$0.6900 +1.47% 21,902
24/09/26 CA$0.6800 +4.62% 111,324
23/09/26 CA$0.6500 -7.14% 211,826
22/09/26 CA$0.7000 +2.94% 88,790

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock